



# Aggregation and degradation scales for prion-like domains: sequence features and context weigh in

Sean M. Cascarina<sup>1</sup> · Eric D. Ross<sup>1</sup>

Received: 31 August 2018 / Revised: 28 September 2018 / Accepted: 3 October 2018  
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

## Abstract

Protein aggregation in vivo is generally combated by extensive proteostatic defenses. Many proteostasis factors specifically recognize aggregation-prone features and re-fold or degrade the targeted protein. However, protein aggregation is not uncommon, suggesting that some proteins employ evasive strategies to aggregate in spite of the proteostasis machinery. Therefore, in addition to understanding the inherent aggregation propensity of protein sequences, it is important to understand how these sequences affect proteostatic recognition and regulation in vivo. In a recent study, we used a genetic mutagenesis and screening approach to explore the aggregation or degradation promoting effects of the canonical amino acids in the context of G-rich and Q/N-rich prion-like domains (PrLDs). Our results indicate that aggregation propensity scales are strongly influenced by the interplay between specific PrLD features and proteostatic recognition. Here, we briefly review these results and expand upon their potential implications. In addition, a preliminary exploration of the yeast proteome suggests that these proteostatic regulation heuristics may influence the compositional features of native G-rich and Q/N-rich domains in yeast. These results improve our understanding of the features affecting the aggregation and proteostatic regulation of prion-like domains in a cellular context, and suggest that the sequence space for native prion-like domains may be shaped by proteostatic constraints.

**Keywords** Proteostasis · Protein aggregation · Prion · Prion-like · Protein degradation · Low complexity domain

## Introduction

All cells depend on a suite of properly folded proteins for survival. While protein aggregation is not always detrimental [and in some cases may even be beneficial (Chakravarty and Jarosz 2018)], errors in protein folding often lead to toxic protein aggregation. This aggregation underlies a number of neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, among others (for review, see Brundin et al. 2010; Holmes and Diamond 2012; King et al. 2012; Costanzo and Zurzolo 2013; Li et al. 2013; Ling et al. 2013; Ramaswami et al. 2013; Taylor et al. 2016). Consequently, cells possess a molecular battalion of proteostasis factors involved

in the detection and elimination of protein folding threats. Yet a number of proteins effectively evade the proteostasis machinery and form aggregates, suggesting that some proteins possess inherent features that simultaneously confer high aggregation propensity and the ability to evade proteostatic systems. Therefore, defining these sequence characteristics would advance our understanding of protein aggregation in vivo.

In yeast, a number of proteins can form self-perpetuating, infectious protein aggregates known as “prions”. The protein domains responsible for this activity have unusual amino acid compositions which, at least in some cases, is the predominant feature facilitating prion aggregation (Ross et al. 2004, 2005). In accordance with these observations, the development of prion prediction methods have focused predominantly on amino acid composition to identify proteins with “prion-like domains” (PrLDs) in the yeast and human proteomes (Alberti et al. 2009; Toombs et al. 2010; King et al. 2012; Espinosa Angarica et al. 2013; Lancaster et al. 2014; Afsar Minhas et al. 2017). Many of the proteins with top-scoring PrLDs have been associated with aggregation

---

Communicated by M. Kupiec.

---

✉ Eric D. Ross  
Eric.Ross@colostate.edu

<sup>1</sup> Department of Biochemistry and Molecular Biology,  
Colorado State University, Fort Collins 80523, CO, USA

and neurodegeneration/myopathy in humans (for review, see King et al. 2012; Harrison and Shorter 2017). However, many proteostasis factors specifically recognize aggregation-prone protein features and either re-fold or degrade these proteins (Flynn et al. 1991; Rudiger et al. 1997a, b, 2001; Fredrickson et al. 2011, 2013; Willmund et al. 2013; Karagoz et al. 2014; Saio et al. 2014; Karagöz and Rüdiger 2015). The ability of yeast prion proteins to aggregate without triggering a strong proteostatic response makes them excellent models to explore the interplay between aggregation and proteostatic regulation.

## Sequence features driving aggregation versus degradation of PrLDs

In a recent study, we explored the features of aggregation-prone proteins that lead either to their detection and degradation by the ubiquitin–proteasome system, or to the formation of self-propagating prion aggregates (Cascarina et al. 2018). Although canonical yeast prion domains tend to be extremely Q/N-rich, a number of the human PrLDs (while still moderately Q/N-rich) tend to be more G-rich. Might these compositional differences affect the molecular fates of aggregation-prone Q/N-rich and G-rich proteins in the eukaryotic intracellular environment?

We chose a canonical Q/N-rich yeast prion domain (PD) from Sup35, and two related G-rich human PrLDs from hnRNPA1 and hnRNPA2B1 as model substrates to examine how changes in the amino acid composition of Q/N-rich and G-rich PrLDs affect prion aggregation and degradation. When substituted in the place of a portion of the Sup35 PD, the hnRNPA1 and hnRNPA2B1 PrLDs are able to support prion activity in a mutation-dependent manner (Kim et al. 2013; Paul et al. 2017). We, therefore, randomly mutagenized a segment of the G-rich PrLDs within these fusion proteins in a manner analogous to previous mutagenesis of the Sup35 PD (Toombs et al. 2010; MacLea et al. 2015). Interestingly, while non-aromatic hydrophobic residues (I, L, M, and V) strongly promote prion formation in the Sup35 PD (Toombs et al. 2010; MacLea et al. 2015), the same residues led to rapid, proteasome-mediated degradation of the G-rich PrLDs. However, when the degradation-promoting sequences were substituted into the Q/N-rich Sup35 PD, they did not noticeably accelerate degradation. Progressively increasing the number of hydrophobic residues led to a step-wise increase in the degradation rate of the G-rich PrLDs before exceeding the resolution of our degradation assays, whereas progressively increasing hydrophobic content in an identical manner in the Sup35 PD led to a step-wise increase in the frequency of spontaneous prion formation. The Q/N content of the Sup35 was critical for resisting the degradation-promoting effects of hydrophobic residues: step-wise

substitutions of G residues for Q/N residues in the Sup35 PD led to a step-wise increase in degradation rate when degradation-promoting sequences were present.


These results indicated that high Q/N content may be one feature that effectively overrides the otherwise degradation-promoting effects of the non-aromatic hydrophobic residues, allowing evasion of the ubiquitin–proteasome defenses. Conversely, the G-rich PrLDs are susceptible to enhanced proteolysis when nudged by certain aggregation-promoting residues.

We next asked whether any residues provide a sufficient balance between low detection by the ubiquitin–proteasome system and high aggregation propensity to facilitate prion aggregation of the G-rich PrLDs. After excluding the isolates with a degradation phenotype from our original phenotypic tests, we screened the remaining isolates for the ability to form rare yet stable prion aggregates. Aromatic residues were significantly over-represented among the identified [*PRION*<sup>+</sup>] isolates, suggesting that they were simultaneously aggregation-prone and poorly detected by the ubiquitin–proteasome system in the context of the G-rich PrLDs.

## Conclusions and perspectives

These observations illuminate multiple ways through which some aggregation-prone proteins may violate conventional wisdom regarding their proteostatic regulation, and highlight important caveats when thinking about protein aggregation in a cellular context. Although a tight link between exposure of aggregation-prone residues and efficient re-folding or clearance of the substrate by the proteostasis machinery has been well-documented (Flynn et al. 1991; Rudiger et al. 1997a, b, 2001; Fredrickson et al. 2011, 2013; Willmund et al. 2013; Karagoz et al. 2014; Saio et al. 2014; Karagöz and Rüdiger 2015), we find that this relationship is not absolute, and can be severed in at least two ways. First, Q/N-rich regions effectively buffered the degradation-promoting effects of hydrophobic residues, thereby permitting aggregation (Fig. 1a top). Second, aromatic residues promoted aggregation of the G-rich PrLDs without efficiently alarming the ubiquitin–proteasome system (Fig. 1a bottom). Therefore, while scales describing aggregation-propensity or degradation-propensity for the 20 canonical amino acids represent essential advances in our understanding of molecular biochemistry, these scales are heavily dependent on both the molecular and cellular contexts (Cascarina et al. 2017, 2018; Paul et al. 2017).

Ideally, our proteostatic defenses would be calibrated to recognize any protein whose aggregation propensity exceeds the solubility threshold under normal cellular conditions (Fig. 1b). However, it is interesting to note that both G-rich and Q/N-rich proteins showed gaps between aggregation and



**Fig. 1** The effects of molecular and cellular contexts on aggregation or degradation of PrLDs in vivo. **a** Aromatic and non-aromatic hydrophobic residues are strongly prion-promoting in the context of a Q/N-rich PD. By contrast, only aromatic amino acids retain their prion-promoting effects in the context of two related G-rich PrLDs,

whereas non-aromatic hydrophobic residues accelerate their degradation via the proteasome. **b** A simplified hypothetical model depicting the interplay between intracellular counter-aggregation defenses and aggregation propensity of Q/N-rich and G-rich domains


proteostatic degradation (Fig. 1b). Although single-amino acid substitutions were sufficient to cause prion aggregation of G-rich PrLDs in our system, and are linked to neuromuscular degeneration in humans, these single substitutions were not sufficient to trigger degradation. One possible

explanation is that the proteostasis machinery must balance sensitivity toward exposed hydrophobicity with specificity toward misfolded proteins. Exposure of a single hydrophobic residue within a G-rich domain may increase the aggregation propensity yet still lie below the sensitivity of relevant

proteostasis factors, effectively resulting in a proteostasis sensitivity gap for G-rich domains. For Q/N-rich PrLDs, this gap between aggregation and degradation may be even larger due to the masking of aggregation-prone features. Additionally, many yeast prions are actually able to propagate precisely because of proteostasis factors (predominantly Hsp104, along with Hsp40 and Hsp70 chaperones) attempting to disassemble existing aggregates (for review, see Chernova et al. 2017b). Therefore, these proteins use a combination of proteostasis evasion and hijacking strategies to aggregate and persist in vivo, potentially explaining why so many of these proteins are linked to functional and pathogenic aggregation.

This study provides a solid foundation for exciting new avenues of research. Although our G-rich PrLDs and Q/N-rich PD allowed us to explore the features controlling their behavior in great depth, it is important to note that these experiments were performed on just three model proteins; therefore, additional experiments will be required to determine to what extent these heuristics apply to other native G-rich and Q/N-rich domains. Surprisingly, although G-rich domains appear to be remarkably susceptible to proteolysis upon insertion of only a few hydrophobic residues (Cascarina et al. 2018), native yeast proteins with G-rich domains are actually associated with higher protein half-lives (i.e., lower degradation rates) and higher protein abundances relative to non-G-rich proteins (Cascarina and Ross 2018). How, then, do native yeast G-rich domains avoid extremely short half-lives despite their susceptibility to proteolysis?

A simple bioinformatic exploration of native yeast G-rich and Q/N-rich domains provides a possible explanation for this apparent discrepancy, and yields a number of interesting observations (Fig. 2). First, strongly degradation-promoting residues (ILMV) are strikingly underrepresented among G-rich domains, suggesting that the natural avoidance of degradation-promoting residues (perhaps via strong selective pressure at the molecular level) may contribute to the higher half-lives associated with proteins containing G-rich domains. By contrast, Q/N-rich domains tend to have a higher relative ILMV content, which may be facilitated by the ability of Q/N-rich domains to suppress the degradation-promoting effects of these residues. Second, strongly prion-promoting residues (FWY) are more common among G-rich domains compared to the degradation-promoting residues, suggesting that many native G-rich domains still possess at least some aggregation-prone features, which may enable some G-rich PrLDs to exhibit prion-like activity (Kim et al. 2013; Molliex et al. 2015; Xiang et al. 2015; Lee et al. 2016). Finally, native Q/N-rich domains tend to have fewer aromatic residues compared to the non-aromatic hydrophobic residues. This is somewhat surprising, given that the Q/N-rich prion domains from canonical yeast prion proteins tend to exhibit secondary biases for aromatic residues (particularly



**Fig. 2** Maximum percentage of degradation-promoting or aggregation-promoting residues within native yeast G-rich and Q/N-rich domains. The yeast proteome was scanned exhaustively using a 40 amino acid sliding window to identify domains with  $\geq 35\%$  G or  $\geq 50\%$  Q/N (the approximate G or Q/N compositions of the hnRNP PrLDs and Sup35 nucleation domain, respectively). Box plots represent the maximum percentages of degradation-promoting (ILMV; left) or prion-promoting (FWY; right) residues among non-G residues within G-rich domains or non-Q/N residues within Q/N-rich domains. For the yeast prion proteins with Q/N-rich domains, maximum percentage values for the known Q/N-rich yeast prion proteins were simply extracted from the Q/N-rich domain dataset and represented as independent box plots. Of the nine canonical yeast prion proteins, seven have Q/N-rich domains that pass our Q/N threshold (Cyc8, Rnq1, Sup35, Lsb2/Pin3, Swi1, Ure2, and Mot3). Plotting and statistics were performed with the Matplotlib and SciPy packages, respectively

tyrosine; Harrison and Gerstein 2003; MacLea et al. 2015). However, when Q/N-rich domains from the known yeast prion proteins (Wickner 1994; Sondheimer and Lindquist 2000; Derkatch et al. 2001; Du et al. 2008; Alberti et al. 2009; Patel et al. 2009; Halfmann et al. 2012; Suzuki et al. 2012; Chernova et al. 2017a) are considered as a separate class, these domains exhibit lower ILMV and higher FWY content relative to Q/N-rich domains as a unified class. Interestingly, our lab has also found that, while both aromatic and hydrophobic residues within Q/N-rich prion domains strongly promote prion nucleation, the aromatic residues appear to uniquely facilitate prion propagation in addition to nucleation (MacLea et al. 2015). This may suggest that aromatic residues provide a sufficient balance between aggregation propensity and aggregate heritability over generations (both of which are necessary for many of the known prions to act as infectious proteins in yeast), and could explain, at least in-part, why some proteins with Q/N-rich domains are aggregation-prone, yet do not appear to form stable prions in vivo (Alberti et al. 2009; MacLea et al. 2015).



It is also important to note that our results are not incompatible with an age-related decline in proteostatic quality control: it may be that some of the aggregation-prone proteins are effectively held at bay until a deterioration in the cell's proteostatic defenses. Proteins on the precipice of aggregation, yet effectively recognized by a healthy proteostasis network, may become toxic when defenses are down (Chernova et al. 2017b; Klaips et al. 2018; Wisniewski et al. 2018). Finally, not all protein aggregation is deleterious. Many proteins naturally form amyloid fibers (Ryzhova et al. 2018), and controlled protein aggregation has been shown, in many cases, to mediate a variety of beneficial processes (Chuang et al. 2018; Chakravarty and Jarosz 2018). Proteins involved in beneficial protein aggregation may possess sequence features that allow evasion of the proteostasis machinery.

Collectively, these studies indicate that the sequence landscapes of prion and prion-like domains that facilitate aggregation *in vivo* are strongly influenced by both the intramolecular context (i.e., the composition of neighboring protein regions) and the intracellular context (including, but perhaps not limited to, the native proteostasis factors). The apparent fluidity of aggregation- and degradation-propensity scales for the 20 canonical amino acids may necessitate the development of multiple scales in different molecular contexts (i.e., prion-like domains with varying starting compositions), and validation of these scales *in vivo*, where proteostasis systems can sway protein fates. Our results highlight the importance of considering proteostatic regulation of PrLDs in addition to inherent aggregation propensity, and enhance our understanding of both beneficial and pathological protein aggregation.

**Acknowledgements** This work was supported by a grant from the National Science Foundation (MCB-1817622) to E.D.R.

## References

- Afsar Minhas F, ul A, Ross ED, Ben-Hur A (2017) Amino acid composition predicts prion activity. *PLoS Comput Biol* 13:1–20. <https://doi.org/10.1371/journal.pcbi.1005465>
- Alberti S, Halfmann R, King O et al (2009) A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. *Cell* 137:146–158
- Brundin P, Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. *Nat Rev Mol Cell Biol* 11:301–307. <https://doi.org/10.1038/nrm2873>
- Cascarina SM, Ross ED (2018) Proteome-scale relationships between local amino acid composition and protein fates and functions. *PLOS Comput Biol* 14:e1006256. <https://doi.org/10.1371/journal.pcbi.1006256>
- Cascarina SM, Paul KR, Ross ED (2017) Manipulating the aggregation activity of human prion-like proteins. *Prion* 11:323–331. <https://doi.org/10.1080/19336896.2017.1356560>
- Cascarina SM, Paul KR, Machihara S, Ross ED (2018) Sequence features governing aggregation or degradation of prion-like proteins. *PLOS Genet* 14:e1007517. <https://doi.org/10.1371/journal.pgen.1007517>
- Chakravarty AK, Jarosz DF (2018) More than just a phase: prions at the crossroads of epigenetic inheritance and evolutionary change. *J Mol Biol*. <https://doi.org/10.1016/j.jmb.2018.07.017>
- Chernova TA, Kiktev DA, Romanyuk AV et al (2017a) Yeast short-lived actin-associated protein forms a metastable prion in response to thermal stress. *Cell Rep* 18:751–761. <https://doi.org/10.1016/j.celrep.2016.12.082>
- Chernova TA, Wilkinson KD, Chernoff YO (2017b) Prions, chaperones, and proteostasis in yeast. *Cold Spring Harb Perspect Biol* 9:a023663. <https://doi.org/10.1101/cshperspect.a023663>
- Chuang E, Hori AM, Hesketh CD, Shorter J (2018) Amyloid assembly and disassembly. *J Cell Sci* 131:jcs189928. <https://doi.org/10.1242/jcs.189928>
- Costanzo M, Zurzolo C (2013) The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. *Biochem J* 452:1–17. <https://doi.org/10.1042/BJ20121898>
- Derkatch IL, Bradley ME, Hong JY, Liebman SW (2001) Prions affect the appearance of other prions: the story of [PIN(+)]. *Cell* 106:171–182
- Du Z, Park KK-W, Yu H et al (2008) Newly identified prion linked to the chromatin-remodeling factor Swi1 in *Saccharomyces cerevisiae*. *Nat Genet* 40:460–465. <https://doi.org/10.1038/ng.112>
- Espinosa Angarica V, Ventura S, Sancho J (2013) Discovering putative prion sequences in complete proteomes using probabilistic representations of Q/N-rich domains. *BMC Genom* 14:316. <https://doi.org/10.1186/1471-2164-14-316>
- Flynn GC, Pohl J, Flocco MT, Rothman JE (1991) Peptide-binding specificity of the molecular chaperone BiP. *Nature* 353:726–730. <https://doi.org/10.1038/353726a0>
- Fredrickson EK, Rosenbaum JC, Locke MN et al (2011) Exposed hydrophobicity is a key determinant of nuclear quality control degradation. *Mol Biol Cell* 22:2384–2395. <https://doi.org/10.1091/mbc.E11-03-0256>
- Fredrickson EK, Gallagher PS, Candadai SVC, Gardner RG (2013) Substrate recognition in nuclear protein quality control degradation is governed by exposed hydrophobicity that correlates with aggregation and insolubility. *J Biol Chem* 288:6130–6139. <https://doi.org/10.1074/jbc.M112.406710>
- Halfmann R, Wright J, Alberti S et al (2012) Prion formation by a yeast GLFG nucleoporin. *Prion* 6:391–399
- Harrison PM, Gerstein M (2003) A method to assess compositional bias in biological sequences and its application to prion-like glutamine/asparagine-rich domains in eukaryotic proteomes. *Genome Biol* 4:R40
- Harrison AF, Shorter J (2017) RNA-binding proteins with prion-like domains in health and disease. *Biochem J* 474:1417–1438. <https://doi.org/10.1042/BCJ20160499>
- Holmes BB, Diamond MI (2012) Cellular mechanisms of protein aggregate propagation. *Curr Opin Neurol* 25:721–726. <https://doi.org/10.1097/WCO.0b013e32835a3ee0>
- Karagoz GE, Duarte AM, Akoury E et al (2014) Hsp90–Tau complex reveals molecular basis for specificity in chaperone action. *Cell* 156:963–974. <https://doi.org/10.1016/j.cell.2014.01.037>
- Karagoz GE, Rüdiger SGD (2015) Hsp90 interaction with clients. *Trends Biochem Sci* 40:117–125. <https://doi.org/10.1016/j.tibs.2014.12.002>
- Kim HJ, Kim NC, Wang YD et al (2013) Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. *Nature* 495:467–473. <https://doi.org/10.1038/nature11922>
- King OD, Gitler AD, Shorter J (2012) The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. *Brain Res* 26:61–80. <https://doi.org/10.1016/j.brainres.2012.01.016>

- Klaips CL, Jayaraj GG, Hartl FU (2018) Pathways of cellular proteostasis in aging and disease. *J Cell Biol* 217:51–63. <https://doi.org/10.1083/jcb.201709072>
- Lancaster AK, Nutter-Upham A, Lindquist S, King OD (2014) PLAAC: a web and command-line application to identify proteins with prion-like amino acid composition. *Bioinformatics* 30:2501–2502. <https://doi.org/10.1093/bioinformatics/btu310>
- Lee K-H, Zhang P, Kim HJ et al (2016) C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. *Cell* 167:774–788.e17. <https://doi.org/10.1016/j.cell.2016.10.002>
- Li YR, King OD, Shorter J, Gitler AD (2013) Stress granules as crucibles of ALS pathogenesis. *J Cell Biol* 201:361–372. <https://doi.org/10.1083/jcb.201302044>
- Ling S-C, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. *Neuron* 79:416–438. <https://doi.org/10.1016/j.neuron.2013.07.033>
- MacLea KS, Paul KR, Ben-Musa Z et al (2015) Distinct amino acid compositional requirements for formation and maintenance of the [PSI<sup>+</sup>] prion in yeast. *Mol Cell Biol* 35:899–911. <https://doi.org/10.1128/MCB.01020-14>
- Molliex A, Temirov J, Lee J et al (2015) Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. *Cell* 163:123–133. <https://doi.org/10.1016/j.cell.2015.09.015>
- Patel BK, Gavin-Smyth J, Liebman SW (2009) The yeast global transcriptional co-repressor protein Cyc8 can propagate as a prion. *Nat Cell Biol* 11:344–349. <https://doi.org/10.1038/ncb1843>
- Paul KR, Molliex A, Cascarina S et al (2017) Effects of mutations on the aggregation propensity of the human prion-like protein hnRNPA2B1. *Mol Cell Biol*. <https://doi.org/10.1128/MCB.00652-16>
- Ramaswami M, Taylor JP, Parker R (2013) Altered ribostasis: RNA-protein granules in degenerative disorders. *Cell* 154:727–736. <https://doi.org/10.1016/j.cell.2013.07.038>
- Ross ED, Baxa U, Wickner RB (2004) Scrambled prion domains form prions and amyloid. *Mol Cell Biol* 24:7206–7213
- Ross ED, Edsles HK, Terry MJ, Wickner RB (2005) Primary sequence independence for prion formation. *Proc Natl Acad Sci USA* 102:12825–12830
- Rüdiger S, Buchberger A, Bukau B (1997) Interaction of Hsp70 chaperones with substrates. *Nat Struct Biol* 4:342–349
- Rüdiger S, Germeroth L, Schneider-Mergener J, Bukau B (1997) Substrate specificity of the DnaK chaperone determined by screening cellulose-bound peptide libraries. *EMBO J* 16:1501–1507. <https://doi.org/10.1093/emboj/16.7.1501>
- Rüdiger S, Schneider-Mergener J, Bukau B (2001) Its substrate specificity characterizes the DnaJ co-chaperone as a scanning factor for the DnaK chaperone. *EMBO J* 20:1042–1050. <https://doi.org/10.1093/emboj/20.5.1042>
- Ryzhova TA, Sopova JV, Zadorsky SP et al (2018) Screening for amyloid proteins in the yeast proteome. *Curr Genet* 64:469–478. <https://doi.org/10.1007/s00294-017-0759-7>
- Saio T, Guan X, Rossi P et al (2014) Structural basis for protein antiaggregation activity of the trigger factor chaperone. *Science* 344:1250494. <https://doi.org/10.1126/science.1250494>
- Sondheimer N, Lindquist S (2000) Rnq1: an epigenetic modifier of protein function in yeast. *Mol Cell* 5:163–172. [https://doi.org/10.1016/S1097-2765\(00\)80412-8](https://doi.org/10.1016/S1097-2765(00)80412-8)
- Suzuki G, Shimazu N, Tanaka M (2012) A yeast prion, Mod5, promotes acquired drug resistance and cell survival under environmental stress. *Science* 336:355–359. <https://doi.org/10.1126/science.1219491>
- Taylor JP, Brown RH Jr, Cleveland DW (2016) Decoding ALS: from genes to mechanism. *Nature* 539:197–206. <https://doi.org/10.1038/nature20413>
- Toombs JA, McCarty BR, Ross ED (2010) Compositional determinants of prion formation in yeast. *Mol Cell Biol* 30:319–332. <https://doi.org/10.1128/MCB.01140-09>
- Wickner RB (1994) [URE3] as an altered URE2 protein: evidence for a prion analog in *Saccharomyces cerevisiae*. *Science* 264:566–569. <https://doi.org/10.1126/science.7909170>
- Willmund F, del Alamo M, Pechmann S et al (2013) The cotranslational function of ribosome-associated Hsp70 in eukaryotic protein homeostasis. *Cell* 152:196–209. <https://doi.org/10.1016/j.cell.2012.12.001>
- Wisniewski BT, Sharma J, Legan ER et al (2018) Toxicity and infectivity: insights from de novo prion formation. *Curr Genet* 64:117–123. <https://doi.org/10.1007/s00294-017-0736-1>
- Xiang S, Kato M, Wu LC et al (2015) The LC domain of hnRNPA2 adopts similar conformations in hydrogel polymers, liquid-like droplets, and nuclei. *Cell* 163:829–839. <https://doi.org/10.1016/j.cell.2015.10.040>